MAP2K7 and cancer: Sorafenib has dual mode of action:1) interfering with multiple receptor tyrosinekinases(VEGFR, PDGFR) to inhibit tumour angiogenesis; 2) blocking the Raf/MEK/ERK signalling pathway to suppress cancer cell proliferation3, 4.